Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Controlled Multicenter Trial Assessing the Efficacy and Safety of Mesalazine Therapy in Patients With Irritable Bowel Syndrome.

NCT00626288 is registered in ClinicalTrials.gov with SOFAR S.p.A. as lead sponsor.

NCT NCT00626288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Controlled Multicenter Trial Assessing the Efficacy and Safety of Mesalazine Therapy in Patients With Irritable Bowel Syndrome.
Lead sponsor
SOFAR S.p.A.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
July 31, 2012
Enrollment
187 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome